University of New Mexico

UNM Digital Repository
Project ECHO Bibliography

Project ECHO

1-1-2016

Proceedings of the 2015 Santa Fe Bone Symposium: Clinical
Applications of Scientific Advances in Osteoporosis and
Metabolic Bone Disease
E Michael Lewiecki
Roland Baron
John P. Bilezikian
Robert E. Gagel
Mary B. Leonard

See next page for additional authors

Follow this and additional works at: https://digitalrepository.unm.edu/hsc_echo_bibliography

Authors
E Michael Lewiecki, Roland Baron, John P. Bilezikian, Robert E. Gagel, Mary B. Leonard, William D. Leslie,
Michael R. McClung, and Paul D. Miller

HHS Public Access
Author manuscript
Author Manuscript

J Clin Densitom. Author manuscript; available in PMC 2019 August 22.
Published in final edited form as:
J Clin Densitom. 2016 ; 19(1): 102–116. doi:10.1016/j.jocd.2015.11.003.

Proceedings of the 2015 Santa Fe Bone Symposium: Clinical
Applications of Scientific Advances in Osteoporosis and
Metabolic Bone Disease
E. Michael Lewiecki*,1, Roland Baron2, John P. Bilezikian3, Robert E. Gagel4, Mary B.
Leonard5, William D. Leslie6, Michael R. McClung7, Paul D. Miller8

Author Manuscript

1New

Mexico Clinical Research & Osteoporosis Center, Albuquerque, NM, USA;

2Harvard

Medical School and Massachusetts General Hospital, Harvard School of Dental
Medicine, Boston, MA, USA;
3Columbia

University College of Physicians and Surgeons, New York City, NY, USA;

4University

of Texas, MD Anderson Cancer Center, Houston, TX, USA;

5Stanford

School of Medicine, Stanford, CA, USA;

6Department
7Oregon

of Internal Medicine, University of Manitoba, Winnipeg, Manitoba, Canada;

Osteoporosis Center, Portland, OR, USA;

8Colorado

Center for Bone Research, Lakewood, CO, USA

Author Manuscript

Abstract
The 2015 Santa Fe Bone Symposium was a venue for healthcare professionals and clinical
researchers to present and discuss the clinical relevance of recent advances in the science of
skeletal disorders, with a focus on osteoporosis and metabolic bone disease. Symposium topics
included new developments in the translation of basic bone science to improved patient care,
osteoporosis treatment duration, pediatric bone disease, update of fracture risk assessment, cancer
treatment-related bone loss, fracture liaison services, a review of the most significant studies of the
past year, and the use of telementoring with Bone Health Extension for Community Healthcare
Outcomes, a force multiplier to improve the care of osteoporosis in underserved communities.
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Introduction
The 16th annual Santa Fe Bone Symposium was held on August 7–8, 2015, in Santa Fe,
New Mexico, USA. The symposium is a 2-day multidisciplinary event that provides an
opportunity for basic bone scientists, clinical researchers, physicians, and other healthcare
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professionals to review and discuss the clinical implications of recent advances in
knowledge of skeletal health and disease. The focus of the presentations and discussions was
the application of evidence-based medicine to clinical practice, recognizing that clinical
decisions are often necessary despite limited scientific evidence. Proceedings of previous
symposia have been published in peer-reviewed journals (1–9).

Translation of Basic Bone Biology Into Improved Patient Care
Roland Baron, DDS, PhD
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In the last 10–15 years, multiple discoveries have been made in the laboratory, most often as
a consequence of the emergence of genetics and genomics, identifying novel mechanisms by
which skeletal remodeling and homeostasis are ensured in both mice and humans. Some of
these novel signaling pathways and/or potential therapeutic targets have been used to
develop novel molecules to inhibit bone resorption (antiresorptives) or enhance bone
formation (osteoanabolics) with the ultimate goal of restoring bone mass and microstructure
in osteoporotic patients at risk of fragility fractures. This is a review of these therapeutic
approaches and describes their mode of action.
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A large part of skeletal homeostasis is accomplished through bone remodeling. This process
is the result of crosstalk between 2 cellular lineages, the hematopoietic lineage, which gives
rise to osteoclast precursors, and the mesenchymal lineage, which gives rise to osteoblast
precursors (10). Osteoclasts are responsible for resorption of bone; these cells also
communicate with cells of the osteoblast lineage through the process of “coupling,” thereby
ensuring the recruitment of bone forming cells at the end of each resorption phase. In turn,
cells of the osteoblast lineage (i.e., osteoblasts, osteocytes, and bone lining cells) are
responsible for the activation of bone remodeling cycles by ensuring the differentiation of
osteoclasts through the local secretion of receptor activator of nuclear factor kappa B ligand
(RANKL) and for ensuring a balance between the amount of bone formed and the amount
resorbed at each bone remodeling site. In the remodeling process, bone formation therefore
occurs as a consequence of bone resorption (10). Logically, a purely antiresorptive drug
should therefore decrease not only resorption but also bone formation and ultimately bone
turnover.

Author Manuscript

This link between resorption and formation is well illustrated by the results of the phase 2
and phase 3 clinical trials of denosumab, a fully human monoclonal antibody that prevents
the osteoclastogenic action of RANKL (11,12). In the phase 2 clinical trial, denosumab was
compared with alendronate. Both treatments markedly decreased the bone resorption marker
serum C-telopeptide and also, with a short lag in time, the bone formation marker serum
procollagen type 1 N-terminal propeptide. The effect of denosumab on bone remodeling was
confirmed in the phase 3 Fracture Reduction Evaluation of Denosumab in Osteoporosis
Every 6 Months trial, in which bone turnover markers (BTMs) and histomorphometric
analysis of iliac crest biopsies were evaluated in a subset of patients (11–13). Denosumab
drastically reduced osteoclast numbers as well as bone formation and remodeling activity in
trabecular bone. Despite these effects on bone remodeling, bone density at all measured
skeletal sites increased significantly with long-term use. Denosumab treatment for up to 8
years was associated with persistent reductions of BTMs, continued bone mineral density
J Clin Densitom. Author manuscript; available in PMC 2019 August 22.
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(BMD) gains, and low fracture incidence (14). The increase in bone density cannot be
entirely explained by the very low remodeling-based bone formation. In monkeys,
denosumab allows the continuation of another type of bone formation: modeling-based bone
formation, perhaps explaining the continued gains in bone mass in humans (15).
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Attempts were then made to find novel antiresorptive drugs that could decrease resorption
without having a negative impact on bone formation. The finding that deletion of cathepsin
K (an osteoclast enzyme critical for bone resorption) blocks resorption but has a neutral or
even positive effect on bone formation (16) opened the way. Mouse genetic studies have
shown that, at least in part, this is due to an enhancement of the osteoclast-dependent
coupling mechanism (17). In preclinical and clinical studies (16–18) with small molecules
inhibiting cathepsin K, markers of bone resorption are decreased to a level comparable to
alendronate, but bone formation markers are maintained close to normal levels. In all these
models, the decrease in bone resorption occurs despite a normal or even increased number of
osteoclasts (16–18), indicating that it does not affect osteoclast differentiation but rather
decreases the resorbing activity of osteoclasts while maintaining the “coupling” activity
(17). The phase 2 and phase 3 Long-term Odanacatib Fracture Trial clinical trials with
odanacatib have established the ability of these once-a-week oral compounds to increase
bone density over several years (19) and to decrease the number of fractures (20).

Author Manuscript
Author Manuscript

An alternative approach to increasing bone mass and strength is to increase bone formation
with osteoanabolic drugs (21). The prototype of this more recent class of osteoporosis drugs
is teriparatide, the N-terminal 1–34 amino acids of parathyroid hormone (PTH 1–34). Unlike
antiresorptive agents, this drug targets cells of the osteoblast lineage and induces an increase
in their numbers and activity, increasing overall bone formation and bone mass, ultimately
reducing the number of fractures (22). A limitation of its use, however, is that PTH increases
the local production of RANKL by osteoblasts and osteocytes and secondarily increases also
osteoclast numbers and bone resorption, preventing further increases in bone density (22).
Two approaches have recently been proposed to limit this secondary increase in bone
resorption. The first one uses an analog of PTH-related peptide (PTHrP [1–34]),
abaloparatide, instead of PTH (23). In this compound, several amino acids have been
substituted, resulting in a limitation of the resorbing responses and favorable stability at
room temperature (teriparatide must be kept refrigerated). In preclinical and clinical phase 2
(23) and phase 3 clinical trials and in a head-to-head comparison with teriparatide,
abaloparatide was found to increase bone density at both trabecular and cortical sites and to
reduce vertebral and nonvertebral fractures (24). Although teriparatide and abaloparatide
affect the same receptors in cells of the osteoblast lineage, they differ in their affinities,
possibly explaining the observed differences in skeletal responses. The second approach has
been to combine the use of teriparatide and denosumab (25). As the PTH-induced increase
in bone resorption is for the most part due to an increase in the local production of RANKL,
adding denosumab to PTH is a logical choice. Indeed, the results of clinical trials have
clearly demonstrated that this drug combination produced effects on BMD at various
skeletal sites superior to either drug taken alone (25,26), confirming that the secondary
increase in RANKL and bone resorption induced by teriparatide is limiting its ability to
maximally increase bone density, in particular at cortical skeletal sites.

J Clin Densitom. Author manuscript; available in PMC 2019 August 22.
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An ideal approach to treating osteoporosis would be with an osteoanabolic drug that
increases bone formation without affecting bone resorption, or even better, one that
decreases bone resorption. Although this seemed a far-fetched goal a few years ago, the
discovery of the role of the Wnt (a term derived from a combination of the Drosophila gene
wingless and the mouse gene int) signaling pathway in the regulation of skeletal homeostasis
has made it reachable (10). Patients with a high bone mass have been identified in several
cohorts and genetic analysis revealed that they had mutations in the Wnt receptor lowdensity lipoprotein receptor-related protein 5 (LRP5) (27,28). Further studies demonstrated
that these mutations decreased the affinity of these receptors for a natural inhibitor of Wnt
signaling, sclerostin, effectively increasing Wnt signaling activity in the bone
microenvironment. At the same time, the causal mutation in sclerosteosis, a rare inherited
disease in humans characterized by high bone mass, has been found to be a null mutation of
the SOST gene (29,30). Homozygotes have very high bone mass associated with serious
adverse effects, while heterozygote carriers have high bone mass but no apparent deleterious
consequences of this increase in bone density (31). This suggests that a compound that
partially inhibits sclerostin might be both effective and safe in treating patients with low
bone mass; this is an approach followed by several drug companies. Importantly, multiple in
vitro and animal studies established these findings and revealed that expression of sclerostin
is restricted to osteocytes (32), such that its therapeutic inhibition would limit Wnt activation
to the bone microenvironment, thereby avoiding off-target effects. Furthermore, sclerostin
inhibition also increased osteoprotegerin (OPG), an endogenous RANKL receptor that
inhibits osteoclastic bone resorption. Pre-clinical, phase 1, and phase 2 results with 2
monoclonal antibodies against sclerostin (romosozumab and blosozumab) have clearly
established the strong ability of these compounds to increase bone density at all measured
skeletal sites by increasing bone formation and decreasing bone resorption (33–35). The
strong anabolic effect is, however, limited in time to the first 6 mo, whereas the
antiresorptive effect, while modest, is prolonged over the entire 1-yr period of treatment,
establishing a sufficiently positive bone balance to markedly and rapidly increase bone
density at trabecular and cortical sites (34,35). A phase 3 trial is currently ongoing with
romosozumab to evaluate its effects on fractures.
In summary, the discoveries of the RANKL, PTH, Wnt signaling pathways, and cathepsin K
have allowed the development of excellent novel therapeutics (e.g., denosumab, teriparatide,
abaloparatide, romosozumab, and odanacatib), some of which have proven efficacy and
safety, with others in their final stages of clinical development. This is a true illustration of
how laboratory discoveries can be translated into improved patient care.
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Current Concepts in Therapy of Osteoporosis
John P. Bilezikian, MD
In the quest for improved therapies for osteoporosis, we recognize several desirable
properties. In some cases, these properties have been considered to be goals of therapy being
developed now or in the future. This presentation dwells on some of these features, pointing
out that, in many instances, we already have achieved these goals in the therapies or in the
context of therapies that are on the horizon.

J Clin Densitom. Author manuscript; available in PMC 2019 August 22.
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Improvement in Cortical Bone—Because cortical bone comprises about 80% of the
human skeleton, it is self-evident that our therapies ideally should have beneficial effects in
this skeletal compartment. Abundant data from several studies have documented an effect of
denosumab on cortical bone. These studies have focused upon the positive effect of this drug
on the distal 1/3 radius (a skeletal site with predominantly cortical bone) (36), the long-term
effect of denosumab on nonvertebral fractures (14), reduction in cortical porosity at the
distal radius (37), computed tomography (CT) cortical mapping at the femur (38), and finite
element analysis (FEA) of CT images of the hip (39). Besides these effects of denosumab, it
should be noted, also, that teriparatide has been shown to improve cortical bone(40), and
animal data have demonstrated the salutary effects of odanacatib, a cathepsin K inhibitor, on
cortical bone in ovarietomized monkeys (41) and of romosozumab, an antisclerostin agent,
on cortical envelopes in ovariectomized animals (42). Compared with bisphosphonates,
treatment with denosumab is associated with greater increases in BMD at both trabecular
and cortical skeletal sites (including the distal 1/3 radius), although it is unclear whether
there is a clinically meaningful difference in fracture risk reduction (43).
Lightening Up on Effects of Antiresorptives to Reduce Bone Formation
Dynamics—Most of the available antiresorptive drugs reduce bone resorption and,
concomitantly, reduce bone formation. Because bone resorption is generally inhibited to a
greater extent than bone formation, improvement in bone balance is achieved, bone density
increases, and fracture risk is reduced. The cathepsin K inhibitor, odanacatib, introduces a
new class of antiresorptives that, by virtue of its effects to selectively inhibit a single
osteoclast product, namely, cathepsin K, osteoclasts continue to be viable both in number
and function (44). It is presumed that these viable osteoclasts continue to signal to
osteoblasts in a positive way, not only maintaining their numbers but also their function (45).
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Lightening Up on the Effects of Osteoanabolics to Stimulate Bone Resorption
Secondarily—The osteoanabolics represent a class of agents that help restore the
disordered microarchitecture that is characteristic of osteoporosis. Teriparatide, the first
member of this class, powerfully and rapidly stimulates bone formation with a later effect on
bone resorption. The discordant kinetics between the effects of teriparatide to stimulate bone
formation and bone resorption have been described as the anabolic window during which
time teriparatide is maximally anabolic (46). Even though bone resorption is increased soon
after bone formation is stimulated, these 2 processes from a mechanistic point of view argue
that the initial effect of the drug is a modeling effect (bone formation on quiescent surfaces),
whereas the secondary effect is a stimulation of bone turnover through the classical bone
remodeling process. Increased bone resorption is important because it serves to limit the
anabolic effect of the drug, as occurs with teriparatide treatment. It may be for this reason
that the pharmacological effects of teriparatide have a built-in time course of efficacy. A new
osteoanabolic medication is being developed that takes further advantage of these concepts.
Abaloparatide is a PTHrP analog designed with empirically placed residues in the 22–34
region of the PTHrP molecule to maximize its anabolic effect (23). The effect of
abaloparatide to stimulate bone formation, as tracked by bone formation markers, is very
similar to the effect of teriparatide, but its ability to stimulate bone resorption, as seen
through a rise in circulating C-terminal telopeptide (CTX), does not appear to be as
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powerful. Thus, there may be a greater distinction between abaloparatide’s actions to
stimulate bone formation (strong) and later to stimulate bone resorption (weaker) than with
teriparatide (23). The initial results from the pivotal phase 3 clinical trial indicate that
abaloparatide reduces vertebral and nonvertebral fractures with a time course suggesting a
faster onset of effect than with teriparatide (24).
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Moving Toward a New Class of Osteoanabolic Therapy—One of the remarkable
aspects of our field is the rapid translation of breakthroughs in bone biology to the clinical
world of therapeutics. A prime example of this is the development of an antisclerostin agent
for the treatment of osteoporosis. Sclerostin is one of the key regulators of the anabolic
signaling pathway referred to as Wnt. Sclerostin prevents interactions between Wnt and its
binding sites such as lipoprotein receptor-related protein 5/lipoprotein receptor-related
protein 6, and thus inhibits a biochemical cascade that ultimately leads to the translocation
of beta-catenin into the nucleus where transcriptional activation occurs (10). The
antisclerostin molecule, known as romosozumab, is a powerful stimulator of bone accrual
with increases in bone density over a relatively short period of time (34). Curiously,
romosozumab has effects on BTMs that are surprisingly transient, with a burst in
procollagen type 1 N-terminal propeptide activity, a marker of bone formation, that returns
to baseline within 6 mos. CTX, the resorption marker, is initially suppressed by
approximately 50%, returning toward baseline but then falling again. Studies on
experimental animals suggest a powerful effect on bone modeling as a partial explanation
for these dramatic osteoanabolic effects of romosozumab. Phase 3 trials are currently being
conducted.
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Combination Therapy With Teriparatide and Denosumab—Understanding the
mechanisms of the aforementioned therapeutics led to a hypothesis that the simultaneous
combination of denosumab and teriparatide might be particularly attractive. The underlying
hypothesis is that teriparatide requires RANKL for its catabolic actions. As denosumab
inhibits RANKL, the osteoanabolic potential of teriparatide would be more evidently
realized if it were combined with denosumab. This hypothesis has been tested in a series of
studies led by Leder et al in which the combination of denosumab and teriparatide was
associated with greater accrual of bone density and improved microarchitectural indices than
either agent alone (25,26).
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While we aspire to drugs that have distinctive effects in ways that should lead to desirable
properties vis-à-vis efficacy, in many instances we have, or appear to be on the verge of
having, drugs that go far toward meeting these objectives. As this field continues to progress
with new insights into basic principles of cellular and molecular bone biology, it is very
likely, if not certain, that these advances will be rapidly translated into therapeutic paradigms
that are uniquely effective.

Cancer Treatment-Related Bone Loss
Robert F. Gagel, MD
General Trends in Cancer Therapy—Several threads have run through cancer therapy
during the past 50 yr. The first is the evolution of cancer treatment from cytotoxic
J Clin Densitom. Author manuscript; available in PMC 2019 August 22.
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chemotherapy to more “targeted” forms of therapy. The first examples of targeted therapy
occurred in breast and prostate cancer with the recognition that estrogen and androgen
depletion therapy, either by reducing sex steroid concentrations or by blocking their effects
on their cognate receptors, had profound effects on tumor growth and survival. This trend
has continued with the recognition that a finite number of mutated genes play a
disproportionate role in genesis and progression of cancer. The corollary of these
observations is that targeting these molecular drivers can have profound effects on tumor
growth and survival. The earliest example was the use of imatinib, a tyrosine kinase
inhibitor, in the treatment of chronic myelogenous leukemia (47) and gastrointestinal
stromal tumors (48). Treatment with these compounds resulted in dramatic effects on both
malignancies. Over the past decade, there has been a proliferation of compounds with kinase
inhibitor effects (49).
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A second trend is the impact these new therapies have on outcomes in cancer. Since the
1990s, there has been a continuous and, for some malignancies, profound reduction in
mortality caused by cancer (50). This trend appears to be accelerating with the introduction
of targeted cancer therapies. A characteristic of these targeted therapies is that therapeutic
effects often require the continued presence of the targeted therapy—the effects are static
rather than tumoricidal. Thus, unlike earlier side effects that were limited to the period of
therapy, many patients will remain on chronic targeted therapy for as long as the malignancy
remains responsive to the therapy.
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How Do These Newer Therapies Affect Bone?—A characteristic of many of the
newer targeted therapies is that they target important molecular pathways involved in cell
growth and differentiation. Unfortunately, these same pathways are also important for a
variety of other cellular functions, some of which have profound effects on bone and mineral
metabolism. For example, the use of aromatase inhibitors in the treatment of estrogen
receptor-positive breast cancer provides a clear example of a drug class with great
oncological benefit that adversely affects the skeletal system (51). Multiple studies have
demonstrated that these agents, which block the conversion of testosterone or
androstenedione to estradiol, are highly effective for reducing recurrence and death in
estrogen receptor-positive breast cancer (52). However, the further lowering of estradiol
levels in postmenopausal women causes an acceleration of bone loss; studies have
demonstrated an increased fracture risk within 3–5 yr of initiating aromatase inhibitor
therapy (53,54). There has been an evolution of thought about the management of these
patients, with significant disagreement among members of the bone and oncological
communities. Initial guidelines focused on treatment only when the T-score fell into the
osteoporotic range; more recent guidelines, based on evidence that earlier intervention
substantially reduces fracture risk, have adopted earlier intervention. Intravenous and oral
bisphosphonates have proven efficacy (55). A recent study has demonstrated that certain
RANKL and OPG polymorphisms are associated with altered RANKL/OPG ratios and
higher rates of bone loss, suggesting that some of the risk is determined genetically and
involves RANKL (56). A more recent study has demonstrated clear evidence that adjuvant
treatment with denosumab, an antibody that binds to and neutralizes RANKL, lowers
fractures in women treated with aromatase inhibitors Thirty-four hundred patients with
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estrogen receptor-positive breast cancer were randomized to receive either placebo or
denosumab (60 mg every 6 mos) at the outset of aromatase inhibitor therapy in a blinded
study. There were 176 fractures in the placebo arm compared with 92 in the treatment arm, a
highly significant difference. During this 6-yr study, there were no cases of osteonecrosis of
the jaw in either placebo or treatment arm. Perhaps the most striking finding of this study
was the finding that 10% of the placebo group had a fracture after 3 yr of therapy, 16% at 5
yr, and a remarkable 26% at 7 yr (54). Although this high fracture rate seems surprising, it is
consistent with high-resolution CT studies which have shown that changes in volumetric
bone mineral density and cortical thickness in this patient population are underestimated by
dual-energy X-ray absorptiometry (DXA) (57). The results of this prospective study of
denosumab in patients treated with aromatase inhibitors have already modified thinking in
the oncological community regarding this issue, particularly as these agents are now being
routinely used for 5–10 yr.
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Bone and Mineral Effects of Tyrosine Kinase Inhibitors—Other targeted therapies
have profound effects on bone and mineral metabolism. For example, vandetanib and
cabozantinib, agents that target RET (REarranged during Transfection) and vascular
endothelial growth factor receptors and are approved for the treatment of medullary thyroid
carcinoma, have profound effects on the absorption of calcium and vitamin D. In the phase
II and III studies of these agents, a high percentage of patients developed hypocalcemia and
vitamin D deficiency, necessitating supplementation with substantial doses of calcium and
vitamin D to overcome the abnormalities (58,59). These profound abnormalities were
identified because a high percentage of patients with metastatic thyroid cancer have had
extensive neck surgery leading to partial or complete hypoparathyroidism. As this class of
vascular endothelial growth factor receptors is among the most commonly used tyrosine
kinase inhibitors (e.g., sunitinb, pazopanib), it is likely that similar malabsorptive changes
occur in patients with intact parathyroid glands, resulting in profound secondary
hyperparathyroidism. Although this may not be a problem during short-term use, the fact is
that these agents are routinely continued for years and could lead to profound effects in the
skeleton. Another example is imatinib. In a group of patients treated for chronic
myelogenous leukemia or gastrointestinal stromal tumors, 25% developed profound
hypophosphatemia, and these same individuals had hypocalcemia and clear evidence of
vitamin D deficiency with secondary hyperparathyroidism (60). The mechanisms of these
profound changes in calcium metabolism are unclear, although the finding of a reduction of
bone resorption (N-telopeptide) and bone formation (serum osteocalcin) markers suggests
the possibility that bone resorption is inhibited, leading to secondary hyperparathyroidism.
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Current cancer investigational agents are focused on a broad spectrum of genes that are
mutated in cancer but also have important roles in normal physiology. The challenge that we
face with these compounds is that they will be used for long periods, even an entire lifetime,
magnifying their detrimental effects. The number of these agents currently under
investigation is large, hundreds to thousands, and it is likely that some will have important
skeletal effects. It will be important to understand which of these agents affect the skeleton,
to take steps to understand their mechanisms of action, and to take preventive action to
protect skeletal health.
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Bone Disease in Children and in Adult Survivors of Childhood Chronic
Disease
Mary B. Leonard, MD
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Growth and development are characterized by sex and maturation-specific increases in
trabecular and cortical BMD and cortical thickness (61). Myriad childhood chronic diseases
and their therapies pose threats to skeletal development. The impact may be immediate,
resulting in fragility fractures during childhood (62–67), or delayed, due to suboptimal peak
bone mass and consequent fractures in adulthood (68–70). Potential threats to bone accrual
in childhood chronic diseases include malnutrition, mal-absorption, impaired muscle
strength, decreased physical activity, systemic inflammation, delayed maturation,
abnormalities in the growth hormone/insulin-like growth factor-1 axis, and glucocorticoid
(GC) therapy (71). In addition, the underlying disease may impact skeletal development
directly. For example, insulin is anabolic to bone and type 1 diabetes is associated with
increased risk of fractures across the life span (70). Numerous DXA studies documented
abnormal areal BMD in pediatric disorders; however, studies using quantitative computed
tomography (QCT) have provided important insights into discrete disease and treatment
effects on trabecular and cortical volumetric bone mineral density (vBMD) and structure.
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GCs are the leading cause of secondary osteoporosis in adults and are widely prescribed for
the treatment of a spectrum of childhood diseases. The growing skeleton may be especially
vulnerable to adverse GC effects on multiple components of bone formation, including
osteoblast proliferation, function, and life span (72,73). The majority of prior DXA studies
in children treated with GCs were confounded by, first, the effects of GCs and the
underlying disease to impair growth, resulting in underestimates of areal BMD for age (74)
and, second, by the impact of the underlying inflammatory disease on bone. Inflammatory
cytokines, such as tumor necrosis factor-α, have direct adverse effects on osteoblasts,
compounding the effects of GCs to impair bone formation. Inflammatory cytokines also
increase bone resorption (75).
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A series of peripheral QCT studies examined trabecular and cortical vBMD and cortical
structure in children and in young adults treated with GCs for inflammatory diseases,
including nephrotic syndrome (76–78), inflammatory bowel disease (74,79–83), systemic
lupus erythematosus (84), and juvenile idiopathic arthritis (85–88). Taken together, these
studies suggested that both GCs and chronic inflammation were associated with decreased
vBMD and periosteal circumference, consistent with effects to decrease bone formation.
Crohn’s disease was associated with increased endosteal circumference at diagnosis prior to
GC therapy, suggesting that inflammation promotes endocortical resorption. The impact of
inflammatory cytokines on bone is further illustrated in a cohort study of children and
adolescents with Crohn’s disease treated with antitumor necrosis factor-α biologics (e.g.,
infliximab) (89). The pediatric Crohn’s disease activity index decreased markedly during the
10-wk induction, in association with subsequent gains in height, trabecular BMD, cortical
area (due to dramatic recovery of endocortical bone), and muscle area over 12 mos. Bonespecific alkaline phosphatase levels, a biomarker of bone formation, increased by a median
of 75% during induction, and predicted improvements in trabecular BMD and cortical area
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over 1 yr, above and beyond the gains expected with age and growth. Younger age was
associated with greater increases in trabecular BMD and greater linear growth with greater
recovery of the cortical area. These data suggest a window of opportunity for the treatment
of bone deficits in children and in adolescents. Of note, serum β-CTX, a biomarker of bone
resorption, also increased significantly following initiation of infliximab therapy. This
reflects robust skeletal modeling during growth and recovery, rather than an adverse effect—
highlighting the challenges of interpreting bone biomarkers during growth (90).
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Multiple recent advances in the use of DXA have improved the utility for the study of
childhood chronic diseases, as summarized in the 2013 International Society for Clinical
Densitometry Pediatric Official Positions (91–94). First, the National Institutes of Healthfunded Bone Mineral Density in Childhood Study (BMDCS) obtained annual DXA scans in
over 2000 healthy participants, ages 5–23 yr, and generated sex- and race-specific reference
curves relative to age for bone mineral content and areal BMD of the total body, lumbar
spine, hip, and forearm (95). These data were obtained with Hologic scanners (Hologic, Inc.,
Bedford, MA) and are also available as “GE equivalents” (GE Healthcare, Madison, WI)
using the transformation equations developed by Shepherd et al (96). The study
demonstrated that fracture risk decreased with higher DXA Z-scores, except in white boys,
who had increased fracture risk with higher DXA Z-scores (97). Second, the BMDCS study
addressed the confounding effect of short stature on areal BMD. Areal BMD (gram per
square centimeter) is not a measure of volumetric density (gram per cubic centimeter)
because it provides no information about bone depth. Bones of larger width and height are
thicker. As bone depth is not factored into DXA results, reliance on areal BMD
systematically underestimates bone density in shorter people. This limitation is critical in
children and adolescents with chronic diseases complicated by poor growth. For example, in
the evaluation of a child on GC therapy, one could falsely attribute the decreased areal BMD
as evidence for skeletal fragility, rather than a GC-induced reduction in height. Accordingly,
the BMDCS investigators published prediction equations to adjust DXA bone mineral
content and BMD Z-scores for height Z-scores and demonstrated that this approach is not
subject to the biases introduced by alternative strategies, such as assessing bone outcomes
relative to height age (98).
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The multicenter Steroid-Associated Osteoporosis in the Pediatric Population study
conducted in Canada was the first prospective study to demonstrate that spine DXA BMD Zscores predicted incident vertebral compression fractures in children and adolescents treated
with GCs (64,65). Vertebral morphometry was carried out by the Genant semiquantitative
method. Children and adolescents with acute lymphoblastic leukemia suffered a cumulative
incidence of vertebral fractures of 26% over 4 yr. Incident fractures were associated with
greater GC exposure, younger age, and lower lumbar spine BMD Z-scores, compared to
those without fractures. Each 1.0 unit reduction in lumbar spine BMD Z-score at baseline
was associated with 80% greater odds of incident vertebral fracture at 12 mo (64). Similarly,
in children treated with GCs for rheumatological disorders, greater GC exposure and
decreases in lumbar spine BMD Z-scores over the first 6 mo of GC therapy were associated
with increased risk of incident vertebral fractures (65).

J Clin Densitom. Author manuscript; available in PMC 2019 August 22.

Lewiecki et al.

Page 11

Author Manuscript

In summary, recent years have seen important advances in the assessment bone health in
children and adults with childhood-onset chronic disease. The challenge in the coming years
is to identify anabolic strategies to promote bone accrual in these high-risk populations.

Advances in Risk Assessment
William D. Leslie, MD, MSc, FRCPC, CCD

Author Manuscript
Author Manuscript

With the advent of DXA, quantitative assessment of fracture risk became possible. The
seminal meta-analysis by Marshall et al (99) showed that each standard deviation reduction
in BMD was associated with an approximately1.5-fold increase in fracture risk, but for
prediction of hip fractures this gradient of risk increased to 2.6-fold for hip BMD
measurements. Suboptimal performance of BMD as the sole predictor of fracture risk led to
the development of risk prediction algorithms for estimating absolute fracture probability
from multiple risk factors (100). The most widely used, the World Health Organization
Fracture Risk Assessment algorithm (FRAX), estimates fracture probability over the
subsequent 10 yr and is calibrated for rates of fracture and mortality in the target population
(101). Currently, more than 60 such tools have been developed for different countries around
the world. Despite many successes, limitations to applying FRAX in clinical practice are
acknowledged (102): specific risk factors that are not included in FRAX (e.g., falls), lack of
dose response in clinical risk factors (e.g., 1 prior fracture vs multiple fractures), and
unresponsiveness of FRAX to pharmacologic intervention (e.g., unable to support a treat-totarget strategy). The only skeletal parameter considered by FRAX is femoral neck
BMD.Although strongly associated with fracture risk, many other skeletal parameters can be
derived from DXA and non-DXA methodologies. The 2015 Position Development
Conference (PDC) held by the International Society for Clinical Densitometry (ISCD)
addressed the clinical utility of several of these skeletal measures (103).

Author Manuscript

Lumbar spine trabecular bone score (TBS) was developed as a texture measurement derived
from DXA images that could provide an assessment of skeletal “quality” independent of
BMD. TBS evolved into a commercial product (Medimaps Group, Geneva, Switzerland) and
in 2013 was cleared for clinical use in the United States. A review by Silva et al (104)
summarizes the preclinical and clinical data that have contributed to the evidence-based
supporting interest in TBS as a clinical tool. Most recently, a method for adjusting FRAX
probability measurements based upon lumbar spine TBS has been derived (105). TBS can
now be entered directly into the FRAX website for automated calculation of fracture
probability that incorporates TBS into the risk calculation. The 2015 ISCD Official Positions
now endorse the use of TBS for fracture risk assessment, but not for monitoring individuals
on bisphosphonate therapy (106). There was insufficient evidence to determine whether TBS
could be used as a measure of antifracture efficacy with other classes of therapeutic agents.
Lumbar spine TBS may be particularly helpful in type 2 diabetes where BMD measurements
and FRAX without TBS input do not adequately capture diabetes-associated fracture risk
(107,108).
Since the early 1990s, it became possible to derive basic geometric and biomechanical
measurements from DXA images (109). The 2015 ISCD PDC reviewed the available data
and found that most of these parameters were strongly correlated with BMD but did not
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significantly enhance risk assessment when adjusted for BMD (110). A single exception was
hip axis length (HAL), defined as the distance from the inner pelvic brim along the femoral
neck axis to the lateral border of the trochanter, where data in postmenopausal women
consistently demonstrate that longer HAL is associated with increased hip fracture risk
(110). HAL remained a significant predictor of hip fracture risk even when adjusted for
BMD and FRAX probability (111). Published data in men are inconsistent, though recent
evidence supports a similar relationship in men (112). The 2015 PDC found strong evidence
for use of HAL in fracture risk assessment in postmenopausal women, but that HAL (and
other geometric parameters) was not useful for monitoring purposes (110). A method for
incorporating HAL into the FRAX hip fracture probability measurement has been proposed
(112).
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QCT was originally used for measuring true vBMD in the lumbar spine (113). The 2015
PDC examined newer data related to proximal femur QCT, additional measures of skeletal
strength assessment using FEA, and found that both techniques were useful for fracture
prediction and for monitoring purposes (114,115). Strength assessment from FEA has been
examined as a possible alternative to the BMD T-score for identifying a treatment threshold,
although this is still preliminary (116). Proximal femur QCT can provide a “DXA-like” Tscore through Food and Drug Administration (FDA)-approved commercial software
(CTXA-Hip™, Mindways Software, Austin, TX) and the derived femoral neck T-score can
be used in conjunction with FRAX for 10-yr fracture risk assessment (117). The potential
for using CT scans acquired for non-bone-related clinical reasons (i.e., without a calibration
scan) for “opportunistic screening” of osteoporosis is now feasible, but only if validated
machine-specific cutoff values and scanner stability have been established. Asynchronous
calibration in stable CT scanners allows for vBMD to be estimated from the clinical CT
images in the absence of a simultaneous in-scan QCT calibration phantom. Together, these
techniques may offer a method for enhanced detection of individuals with osteoporosis who
are currently not being screened with DXA or appropriately treated.
Despite challenges from other advanced technologies, the potential for even more advances
in DXA is good. The concept of 2-dimensional FEA (in contrast to FEA from QCT, which is
3-dimensional) is attracting attention with favorable initial results (118). Whether BMD
alone or BMD combined with other treatment-response parameters (e.g., BTM) can be used
to develop a treat-to-target strategy remains an area of clinical importance and research
(119).

This Year in Osteoporosis: Are We Ahead or Behind Last Year? Comments
Author Manuscript

on Selected Papers Published From July 2014 to June 2015
Michael McClung, MD
A review of papers about osteoporosis published between July 2014 and June 2015 was
undertaken. About 25 of these were chosen for presentation at the Santa Fe Bone
Symposium as being of special interest or importance. Highlighted here are the most
relevant of those.
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Wnt 16, an osteoblast-derived inhibitor of osteoclastogenesis, is an important and powerful
modulator of cortical bone mass and structure. Wnt 16-deficient mice develop spontaneous
fractures as a result of low cortical thickness and high cortical porosity, but trabecular bone
volume is not altered (120). In humans, serum levels of Wnt 16 are correlated with cortical
bone thickness and nonvertebral fracture risk. Given the unique effect on cortical bone,
therapy with or to upregulate Wnt 16 may be an attractive strategy to reduce nonvertebral
fracture risk.
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An updated systematic review documented the effectiveness of pharmacological treatments
for reducing fracture risk in patients with osteoporosis (121). Despite this strong evidence,
criticism about treating osteoporosis appeared again (122). There is new evidence that the
proportion of patients receiving treatment to reduce subsequent fracture risk after a hip
fracture declined from 40% in 2002 to about 20% into 2011 (123). The proportion of women
over age 65 referred for DXA testing remains very low but was improved when health
systems allowed and encouraged self-referral (124).
FEA, calculated from DXA scan images, is a BMD-independent predictor of fracture risk
(118). The ability of TBS to predict fracture was confirmed in postmenopausal women and
in men (125,126).
Periodic reassessment of the need for continued bisphosphonate therapy is recommended.
Age and BMD at the time therapy is discontinued remain predictors of fracture risk,
justifying the use of BMD and FRAX estimates of risk in deciding whether treatment should
be stopped (127). Monitoring changes in BMD and BTMs after stopping treatment was not
helpful in identifying patients who experienced a fracture (128).
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Atypical femoral fractures are associated with long-term bisphosphonate therapy and have
been reported in patients treated with denosumab; they are also known to occur in patients
receiving no osteoporosis therapy (129). Two studies documented that femoral geometry
predicted the occurrence and site of the femoral shaft stress fractures (130,131). This raises
the possibility that more data identifying risk factors for atypical femur fractures might
allow physicians to customize drug therapy and use medications that are least likely to be
associated with this rare complication. On the other side of the risk : benefit equation,
bisphosphonate therapy was associated with a 50% decrease in skeletal metastases in women
with local or regional breast cancer (132). A separate study suggested that the risk of
invasive endometrial carcinoma was reduced by 20% in ever users of bisphosphonates (133).

Author Manuscript

Inhibition of sclerostin is an attractive strategy to increase bone formation to treat
osteoporosis. Treatment with blosozumab resulted in marked but transient increases in
markers of bone formation and a decrease in markers of bone resorption (35). Increases in
lumbar spine and total hip BMD by 17.7% and 6.7%, respectively, were noted after
treatment for 12 mo. In the 12 mo after stopping treatment, BMD values decreased but
remained well above baseline values (134).
In a phase 2 study, daily subcutaneous dosing with 80 μg of abaloparatide increased BMD
more than with 20 μg of teriparatide daily (23). The phase 3 trial results, recently presented
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at a scientific congress, demonstrated that abaloparatide and teriparatide similarly reduced
the incidence of vertebral and nonvertebral fractures after 18 mo of treatment.
Combining denosumab and teriparatide increases BMD more effectively than either drug
alone. Continuing denosumab after 2 yr of combination therapy or switching from
teriparatide to denosumab after 2 yr resulted in further gains in total hip and spine BMD
over the subsequent 2 yr (135). In patients who switched from denosumab to teriparatide, a
modest additional gain in spine BMD was noted. However, no further gain in hip BMD
occurred, and a substantial decrease in midradius BMD (cortical bone) was observed. For
patients in whom marked and rapid bone gain are desired, treatment with teriparatide or with
a combination of teriparatide and denosumab for 2 yr followed by denosumab (25,26,135) or
another antiresorptive agent (136,137) may be advantageous.

Author Manuscript

How Concepts of Bisphosphonate Drug Holidays May Be Linked to the
Decline in Utilization of Osteoporosis Therapies
Paul D. Miller, MD
Osteoporosis is an underdiagnosed and undertreated disease (138). The annual costs in the
United States of caring for osteoporotic-related fractures exceed the annual costs for
myocardial infarction, breast cancer, or stroke (139). Equally disturbing are the data showing
that the percentage of patients receiving an FDA-approved therapy for osteoporosis, even
after sustaining a hip fracture, has declined in the United States from 41% in 2001 to 21% in
2011 (123). Finally, the greatest causes of the loss of independence in men and in women 70
yr of age and older are falls at home and fractures (140–142).

Author Manuscript

A number of factors contribute to the decline in the diagnosis and treatment of osteoporosis,
including a decrease in the number of patients being tested by DXA (143), concerns about
the long-term safety of bisphosphonates, for example, their rare associations with
osteonecrosis of the jaw and/or atypical subtrochanteric femur fractures (ASFFs) (129,144),
and underappreciation by physicians themselves of the seriousness of osteoporotic fractures,
including asymptomatic vertebral fractures (145–148). The international movement to
develop Fracture Liaison Services, spearheaded in the United States by the National Bone
Health Alliance and internationally by the International Osteoporosis Foundation, is a
multidisciplinary effort to reduce the incidence of the second osteoporotic fracture (149,150)
by developing pathways for identifying and managing hospitalized patients with an
osteoporotic fracture.

Author Manuscript

The attention given to the association of bisphosphonate use and the rare ASFFs has been a
factor in the poor acceptance of therapies for osteoporosis by patients. Greater attention
should be directed at the excellent data showing the far greater reduction in the incidence of
typical hip fractures with bisphosphonate therapy, rather than to the very rare incidence for
developing a bisphosphonate-associated atypical fracture—a benefit : risk ratio that exceeds
100:1 (151). Osteoporotic-related ASFFs represent approximately 10% of the total number
of osteoporotic-related femur fractures that occur annually in the postmenopausal population
(152,153). The term ASFF was coined by several investigators to describe a specific type of
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sub-trochanteric femur fracture (152,154) and was articulated in the American Society for
Bone and Mineral Research working group reports on ASFF (129,155). It is important to
highlight that both American Society for Bone and Mineral Research task force papers
documented that ASFF may develop independent of bisphosphonate exposure.
There have been an increasing number of ASFF reported in epidemiological studies since
the approval of bisphosphonates for postmenopausal osteoporosis in 1995. It is also possible
that the apparent increase in ASFF occurring in subjects on bisphosphonates has nothing at
all to do with bisphosphonate exposure, as the very populations that are at risk for
developing these forms of femur fractures are the very same subjects with low bone mass
with a higher baseline risk for ASFF and who also may be selected to receive
bisphosphonates because of their low bone mass (e.g., the data are confounded by
indication).

Author Manuscript

There are plausible reasons why causality has not been confirmed in attributing the
occurrence of ASFF to bisphosphonate exposure, including the absence of a known
mechanism of action whereby bisphosphonates might induce ASFF. Bisphosphonates reduce
bone remodeling but by doing so improve bone strength. This biology underpins the process
whereby antiresorptive agents reduce fractures.
The US FDA held an advisory board meeting on September 9, 2011, to consider a change in
bisphosphonate labeling to define a restricted duration of use. This consideration for the
restriction of the duration of bisphosphonate use was predicated on 3 assumptions:

Author Manuscript

1.

The limited long-term efficacy data of bisphosphonate use (i.e., limited data on
continual fracture benefit beyond 5 yr)

2.

The unique pharmacology of bisphosphonates (i.e., not metabolized, retained in
bone, and recycled) would allow temporary discontinuation of bisphosphonates
while preserving some of their biological effects.

3.

The assumption that there exists a link between bisphosphonates, their duration
of use, and the risk of ASFF.

Author Manuscript

The first assumption is a correct but unfair criticism because long-term fracture data are
limited by the small sample sizes in bisphosphonate extension studies, as well as for all
other medications for treating osteoporosis, and the inability to maintain the original
randomized registration clinical trial placebo population sample size for an extended period
of time. The second assumption is, in part, biologically correct. Bisphosphonates do retain
some pharmacological effects after discontinuation, although the data supporting the
maintenance of fracture reduction are based on weak data (146,156). The third assumption,
that there exists a significant interaction between the duration of bisphosphonate use and the
development of ASFF (i.e., longer bisphosphonate duration of use, greater rate of ASFF), is
flawed. The duration data are mostly epidemiological and retrospective, much of which may
be confounded by indication. In addition, the pivotal citation used to validate that there may
be an incident rate for the development of bisphosphonate-associated ASFF is not a true
incident rate (147).
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With this knowledge, the independent FDA advisory panel did not support restricting the
duration of use, a position with which some FDA employees later disagreed, publishing their
own opinions on bisphosphonate duration of use (148). Regardless, there was no FDA label
change limiting the duration of use of bisphosphonates for osteoporosis. Additionally, the
average practicing clinician, not knowing the process of an independent FDA advisory vote,
as opposed to FDA employees’ ability to independently set a standard of care based on their
own points of view, adopts practice patterns and at times a standard of care that might be at
polar positions between the FDA-independent experts and the FDA. I believe this “standard”
of terminating bisphosphonate use after 3–5 yr is largely driven by the FDA commentary
rather than based on sound scientific data.

Author Manuscript

In conclusion, there are no sound scientific reasons for stopping any therapy for osteoporosis
in patients at high risk for fracture. The Fracture Intervention Trial Long-Term Extension
with alendronate proved this point. In the Fracture Intervention Trial Long-Term Extension,
elderly patients (69 yr and older), even those with osteopenia and no prevalent vertebral
compression fractures, still had more clinical (painful) vertebral fractures on a “drug
holiday,” and neither the baseline T-score nor the presence or absence of a vertebral fracture
could predict who might or might not develop fractures off alendronate. There are no sound
scientific data proving that long-term bisphosphonates cause ASFF. Bisphosphonates should
be continued in patients at high risk for fracture; if patients insist that a therapy be changed,
then it should be changed to a different approved therapy for osteoporosis, but stopping
treatment should not be done, just as stopping treatment for most chronic systemic diseases
is not done.

Telementoring for Osteoporosis
Author Manuscript

E. Michael Lewiecki, MD
Bone Health Extension for Community Healthcare Outcomes (ECHO) is telementoring to
improve the care of osteoporosis (157). Its aim is to educate healthcare professionals (e.g.,
physicians, nurse practitioners, and physician assistants), especially those in underserved
rural areas, to provide advanced care for patients with osteoporosis and metabolic bone
diseases. For patients, this may obviate the need to travel long distances to see specialists in
urban areas, often involving long wait times for appointments, allowing for more convenient
care close to home in a familiar practice setting. For primary care providers, their level of
knowledge is expanded, professional isolation is diminished, and no cost continuing medical
education is provided.

Author Manuscript

The ECHO concept of telementoring was developed at the University of New Mexico
School of Medicine in Albuquerque, New Mexico, beginning with a pilot project using
chronic hepatitis C virus (HCV) infection as the model disease. A total of 21 HCV ECHO
sites with 407 HCV-infected patients were enrolled in an outcomes study, with the finding
that the ECHO sites performed as well as an academic medical center; about 58% of patients
in each group sustained virological response (158). Since that time, ECHO telementoring
has been applied to other medical conditions and replicated throughout the United States and
in other world regions. ECHO demonopolizes medical care by creating knowledge networks,
enabling delivery of advanced medical services by primary care providers located closer to
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the patients they serve. Consistent with the principles proven to be effective with the Project
ECHO strategy, the first Bone Health ECHO clinic has recently been established in New
Mexico, with learning partners distributed throughout New Mexico and in other states.
ECHO clinics have no boundaries, and can be attended by anyone with Internet access or a
telephone connection.

Author Manuscript

Operationally, an ECHO clinic typically requires a passionate “champion” to initiate the
project, a committed group of experts willing to participate in ongoing interactive learning,
videoconferencing equipment, information technologists, support staff, and learning
partners. Funding for ECHO clinics and outcomes research has primarily been from public
and private grants, often with support from educational institutions. Other potential sources
of ECHO funding include governmental agencies and insurance companies paying for
healthcare services. These organizations have aligned interests in evaluating and supporting
innovative methods for improving the cost-effectiveness of healthcare delivery. Potential
cost savings with implementation of Bone Health ECHO include reduced or eliminated
long-distance travel to specialty clinics for patients (currently paid by Medicaid in New
Mexico) and prevention of costly complications of osteoporosis (e.g., hip fractures) while
providing higher quality of care and reducing medical errors. With an estimated direct
healthcare cost of about $40,000 for a hip fracture (159) and a total lifetime cost of about
$81,300 per hip fracture (160), preventing just a few hip fractures will more than offset an
approximate total annual cost of Bone Health ECHO of about $250,000 (including start-up
expenses, equipment, and fully compensated faculty and support staff).
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Telementoring is not telemedicine, which typically makes use of audiovisual technology to
provide one-on-one care for a patient located far from a specialist. Instead, telementoring
with ECHO uses this technology to link a team of medical experts with many healthcare
professionals, each of whom will potentially acquire skills necessary to provide advanced
levels of osteoporosis care for their patients and possibly for patients of other providers in
the community.
The Bone Health ECHO multidisciplinary teaching team interacts with learning partners
through a weekly 1-h videoconference. Case-based discussions comprise the bulk of each
session, with short (10 min) didactic presentations covering topics of interest. Patient
confidentiality is maintained, with all ECHO clinics compliant with the US Health Insurance
Portability and Accountability Act. The learning partners retain all responsibility for
treatment decisions. Case discussions focus on teaching points that benefit all participants.
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Measurement of outcomes with Bone Health ECHO will be through surveys of learning
partners to evaluate achievement of stated learning objectives, self-efficacy questionnaires,
and analysis of healthcare claims databases for diagnostic and procedural codes such as
osteoporosis prescriptions, bone density tests, and fractures at baseline and after the ECHO
intervention. Modeling can be performed to estimate expected changes in fracture rates
when more patients are treated with antifracture medications. The Bone Health ECHO
Collaborative has been established to share the New Mexico Bone Health ECHO experience
with universities in other states. The intent is to replicate the achievements and avoid any
missteps with New Mexico Bone Health, to use a common curriculum, and to pool outcomes
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data. If proven successful, the innovative telementoring strategies of Bone Health ECHO
will be a useful adjunct for addressing current unmet needs in the care of osteoporosis.
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